A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

Clinical trial NCT03485326 · COMPLETED

Trial details

NCT number: NCT03485326
Sponsor: AstraZeneca
Status: COMPLETED
Study type: OBSERVATIONAL

Non-small Cell Lung Cancer

Start date: 2020-04-21
Primary completion: 2023-08-03
Enrollment: 1700

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.